Sriram Balasubramanian

Years Active: 2021-2022
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Mark S Tichenor, John J M Wiener, Navin L Rao, Genesis M Bacani, Jianmei Wei, Charlotte Pooley Deckhut, J Kent Barbay, Kevin D Kreutter, Leon Chang, Kathleen W Clancy, Heather E Murrey, Weixue Wang, Kay Ahn, Michael Huber, Elizabeth Rex, Kevin J Coe, Jiejun Wu, Haopeng Rui, Kia Sepassi, Marcello Gaudiano, Mariette Bekkers, Ivo Cornelissen, Kathryn Packman, Mark J Seierstad, Christos Xiouras, Scott D Bembenek, Richard Alexander, Cynthia Milligan, Sriram Balasubramanian, Alec D Lebsack, Jennifer D Venable, Ulrike Philippar, James P Edwards, Gavin Hirst
Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. Journal of medicinal chemistry 65 (21) (2022)
Sriram Balasubramanian, Brendan Hodkinson, Stephen J Schuster, Nathan H Fowler, Judith Trotman, Georg Hess, Bruce D Cheson, Michael Schaffer, Steven Sun, Sanjay Deshpande, Jessica Vermeulen, Gilles Salles, Ajay K Gopal
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. Cancer medicine (2021)

Sriram Balasubramanian.css-eqlu8i{font-size:small;padding-left:4px;}